Geode Capital Management LLC Sells 49,048 Shares of Roivant Sciences Ltd. $ROIV

Geode Capital Management LLC lessened its stake in Roivant Sciences Ltd. (NASDAQ:ROIV) by 0.6% in the fourth quarter, HoldingsChannel reports. The fund owned 8,153,546 shares of the company’s stock after selling 49,048 shares during the period. Geode Capital Management LLC’s holdings in Roivant Sciences were worth $176,972,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Jones Financial Companies Lllp lifted its stake in shares of Roivant Sciences by 226.0% in the 3rd quarter. Jones Financial Companies Lllp now owns 1,656 shares of the company’s stock valued at $25,000 after acquiring an additional 1,148 shares during the last quarter. SBI Securities Co. Ltd. lifted its stake in shares of Roivant Sciences by 1,740.3% in the 4th quarter. SBI Securities Co. Ltd. now owns 1,233 shares of the company’s stock valued at $27,000 after acquiring an additional 1,166 shares during the last quarter. Allworth Financial LP lifted its stake in shares of Roivant Sciences by 48.1% in the 3rd quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock valued at $27,000 after acquiring an additional 583 shares during the last quarter. Bessemer Group Inc. lifted its stake in shares of Roivant Sciences by 41.5% in the 3rd quarter. Bessemer Group Inc. now owns 1,852 shares of the company’s stock valued at $28,000 after acquiring an additional 543 shares during the last quarter. Finally, Clearstead Advisors LLC lifted its stake in shares of Roivant Sciences by 141.6% in the 4th quarter. Clearstead Advisors LLC now owns 2,907 shares of the company’s stock valued at $63,000 after acquiring an additional 1,704 shares during the last quarter. Institutional investors own 64.76% of the company’s stock.

Insider Transactions at Roivant Sciences

In other Roivant Sciences news, Director Melissa B. Epperly sold 41,861 shares of the company’s stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $28.68, for a total transaction of $1,200,573.48. Following the transaction, the director owned 15,804 shares in the company, valued at approximately $453,258.72. This represents a 72.59% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Matthew Gline sold 289,774 shares of the company’s stock in a transaction that occurred on Thursday, April 16th. The stock was sold at an average price of $29.16, for a total value of $8,449,809.84. Following the transaction, the chief executive officer owned 16,736,116 shares in the company, valued at $488,025,142.56. This trade represents a 1.70% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 945,173 shares of company stock worth $27,654,456 over the last quarter. Insiders own 10.80% of the company’s stock.

Roivant Sciences Price Performance

ROIV opened at $28.70 on Thursday. The business has a 50 day simple moving average of $28.68 and a two-hundred day simple moving average of $25.59. The firm has a market capitalization of $20.64 billion, a price-to-earnings ratio of -47.83 and a beta of 1.13. Roivant Sciences Ltd. has a one year low of $10.70 and a one year high of $32.79.

Roivant Sciences (NASDAQ:ROIV) last released its quarterly earnings results on Wednesday, May 20th. The company reported $0.28 EPS for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.57. Roivant Sciences had a negative return on equity of 20.54% and a negative net margin of 3,629.19%.The business had revenue of $2.52 million during the quarter, compared to analyst estimates of $3.41 million. During the same quarter in the prior year, the company posted ($0.29) EPS. As a group, sell-side analysts expect that Roivant Sciences Ltd. will post -1.06 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have commented on the company. HC Wainwright reaffirmed a “buy” rating and set a $34.00 price target on shares of Roivant Sciences in a research report on Thursday, May 21st. Citigroup upped their price target on Roivant Sciences from $35.00 to $42.00 and gave the company a “buy” rating in a research report on Thursday, May 21st. TD Cowen upped their price target on Roivant Sciences from $38.00 to $41.00 and gave the company a “buy” rating in a research report on Thursday, May 21st. Piper Sandler reaffirmed an “overweight” rating on shares of Roivant Sciences in a research report on Thursday, May 21st. Finally, Leerink Partners set a $42.00 price target on Roivant Sciences in a research report on Thursday, May 21st. Ten analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $33.59.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.